Consequently, even though capillaries only make up 40% of the blood volume of the lung, they contain 99% of the lung bloodborne neutrophils. These data indicate that hemodynamic forces greatly influence the transit rate of leukocytes in the microvasculature. Such forces may sequester lymphocytes within pulmonary vasculature as well, perhaps owing to the expression of adhesion molecules or the fact that the volume of a lymphocyte is greater than an RBC (~290 fl versus ~90 fl) 20, 21 .
Perfusion, a method of flushing the pulmonary vasculature with buffer, has been used to remove RBCs and leukocytes from the lung vasculature. However, we recently showed that the vast majority of CD8 T cells isolated from the lung of perfused mice were likely trapped within the vasculature because they were rapidly stained with i.v.-injected monoclonal antibody (mAb) 13 . These results call into question several studies that report that naive lymphocytes are present within the lung tissue of specific pathogen-free (SPF) mice that lack inducible bronchus-associated lymphoid tissue (iBALT) [22] [23] [24] [25] ; these are observations that violate the central dogma that naive lymphocytes are excluded from nonlymphoid tissues (NLTs) and which were proposed to have major biological implications. Here we show how intravascular staining can be used to address these issues. Consistent with previous reports using this protocol 13 , we recovered B cells and T cells that expressed a naive phenotype (CD62L + and CD44 lo for CD4 and CD8 T cells and IgD + and/or IgM + for B cells) from the lungs of uninfected mice that were perfused to remove blood from organs. When anti-CD45.2 mAb was injected i.v. 3 min before mice were killed and perfused (CD45 is expressed on the surface of all leukocytes), >99% of naive lymphocytes, regardless of lineage, became labeled (Fig. 1a) . These results confirm that intravascular staining can be used to identify naive lymphocytes within the pulmonary vasculature.
Perfusion has been suggested to have other consequences on lung architecture. Mice seeded with naive Thy1.1 + P14 CD8 T cells (referred to as 'P14 chimeric mice', which allows for tracking of a monoclonal CD8 T cell population specific for lymphocytic choriomeningitis virus (LCMV)) and infected via the intratracheal (i.t.) route with the mouse pathogen LCMV develop the transient tertiary lymphoid organ iBALT. iBALT has been well characterized, and it is classically defined as a collection of lymphocytes and dendritic cells that abuts a large airway, is typically adjacent to large blood vessels and contains both lymphatic vessels and high endothelial venules (HEV, as detected by peripheral lymph node adressin (PNAd) staining) 26 . Along with iBALT, i.t. LCMV infection induces abundant lymphocyte aggregates that are distinct from iBALT in that they lack HEVs, they are much smaller and they are not located near large airways. Consistent with the expectation that perfusion disrupts lung architecture, perfusion markedly reduces the abundance of iBALT and alveolar lymphoid aggregates detectable per lung lobe (Fig. 1b) , and it reduces the cellularity of those that remained (data not shown). Indeed, alveolar lymphoid aggregates were difficult to detect after perfusion, which may help explain why they have rarely been noted previously [27] [28] [29] [30] [31] .
Collectively, these data confirm that perfusion not only leaves behind vascular-bound lymphocytes but also depletes leukocyte populations within lung compartments that may be of interest. An important advantage of intravascular staining is that it mitigates the need for perfusion.
Experimental design
The sample preparation and flow cytometry acquisition steps described in the following procedure are for CD8αβ T cells isolated from a spleen, as an example application.
Controls.
When using intravascular staining, critical staining controls must be included in every experiment. Peripheral blood (from retro-orbital or cardiac puncture) should be sampled from every mouse. One should observe that >99% of the cell population targeted by the intravascular Ab will stain positively within the peripheral blood. A negative staining control, such as lymph nodes, should also be sampled. One should observe less than 10% of cells isolated from lymph nodes staining positively with intravascular Abs. For a discussion of Ab selection, see Limitations. We have used intravascular injection of anticollagen type IV Ab to test for vascular leakage in all the models examined in this manuscript. Although the conditions we tested allow for reliable intravascular staining, there could be conditions under which vascular leakage may compromise the integrity of staining. For instance, there may be inflammatory contexts or angiogenic tumor models that allow rapid exudation of Ab into tissues, which could compromise interpretation of intravascular staining. Investigators examining unique conditions would be advised to perform appropriate validating controls, such as histological analysis after injection of anti-collagen Ab (Box 1) or injection of Evans Blue dye (EBD), as described 13 basement membrane surrounds endothelial vessels in tissues such as the lung and intestine, and it is not exposed to intravascular Ab under conditions that we have tested. Collagen staining in the liver sinusoids, glomerular capillaries of the kidney and red pulp of the spleen can be used as positive staining controls, as these are exposed to vascular Ab under steady-state conditions (data not shown and Anderson et al. 13 ). As an alternative approach, one could consider using EBD, as described. EBD stains the serum Box 1 | Sample preparation and acquisition steps for examining vascular permeability of the lung ! cautIon Microscopy should be performed by trained individuals and in accordance with all institutional biosafety regulations. Refer elsewhere for detailed overviews of immunofluorescence staining 59 and microscopy 60,61 . 1. Follow PROCEDURE Steps 1-4 by using purified polyclonal goat anti-mouse collagen type IV (15 µg per mouse). As a control, include a sample slide for ex vivo anti-collagen type IV staining. One of the following should be included as a positive control for intravascular collagen type IV staining: liver sinusoids, glomerular capillaries of the kidney or red pulp of the spleen. 2. Embed the lung and spleen in OCT medium. 3. Snap-freeze the samples in liquid nitrogen or on dry ice. 4. Prepare 7-µm sections on microscope slides with a cryostat. 5. Fix the slides in cold acetone for 10 min.  pause poInt Slides can be stored at − 20 °C or − 80 °C for at least 18 months. 6. Rehydrate the slides with 1× DPBS for 10 min. 7. Block the slides for 60-90 min at room temperature (or overnight in the refrigerator) with 5% (wt/vol) BSA blocking solution. 8. Stain the slides with mAb anti-CD31-AF488 for 60 min (dilute anti-CD31 Ab 1:100 in 5% (wt/vol) BSA blocking solution or PBS). The control slide should also be stained with purified polyclonal goat anti-mouse collagen IV (dilute anti-collagen IV Ab 1:200 in 5% (wt/vol) BSA blocking solution or PBS). 9. Wash the slides gently three times with 5% (wt/vol) BSA blocking solution or PBS. 10. Stain the slides with purified polyclonal donkey anti-goat-AF555 for 30 min (dilute anti-goat Ab 1:2,000 in 5% (wt/vol) BSA blocking solution or PBS protein albumin, which is only found in blood vessels under conditions with intact endothelium, but which permeates into tissues when vascular permeability is increased. Histological analysis or a quantitative comparison of EBD levels in sample tissues compared with healthy controls can be used to validate the appropriateness of intravascular staining. Table 1 for information about specific antibodies that we have used) Ab for ex vivo staining and analysis (see Table 2 for information about specific antibodies that we have used) Isoflurane, USP (Phoenix Pharmaceutical) ! cautIon Isoflurane is a powerful anesthetic, and it should always be used inside a laminar flow hood and in accordance with institutional biosafety requirements. Restrainer  crItIcal This is optional, but we find that stabilizing the mice facilitates easier tail-vein injections. Euthanasia chamber 3| Kill the mouse 3 min after injection by using isoflurane. Euthanasia with inhaled isoflurane should be performed in a closed container with an absorbent material soaked in the anesthetic (the amount of isoflurane to use will vary with container size). Avoid contact between the mouse and the anesthetic. ! cautIon Isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane) is used for inhalational anesthesia. It is liquid at room temperature and vaporizes readily. Isoflurane is a powerful anesthetic, and it should always be used inside a laminar flow hood. Only approved containers should be used for euthanasia with inhaled anesthetics. ! cautIon Isoflurane euthanasia should be approved by an IACUC and an institutional biosafety committee.  crItIcal step Longer wait times have not been validated. ? troublesHootInG 4| Collect the tissues of interest into appropriate containers (Petri dishes, conical tubes or gentleMACS tubes) containing RPMI + 5% (vol/vol) FBS.  crItIcal step Mouse euthanasia and tissue collection should be performed quickly to improve cell viability.
5|
Immediately smash or mince tissues and wash them to rinse away or dilute any excess Ab. Store the tissues on ice in RPMI + 5% (vol/vol) FBS.
? troublesHootInG  pause poInt Tissue pieces can be left on ice while additional mice are processed for up to 3 h. Nevertheless, empirically, faster processing yields better results.
6|
If desired, isolate leukocytes from tissues. Numerous protocols have been described, and they vary depending on the tissue and leukocyte population of interest 38, 39 . These protocols will not be reviewed here. Each investigator should optimize this protocol for the tissue and cell type of interest. Alternatively, organs may be embedded in freezing medium such as OCT medium for subsequent immunohistochemical analysis 38 . 14| Perform compensation by using an unstained control and single-stained samples. Fig. 2a ). This approach takes advantage of the fact that most CD8 + T-cell populations express heterodimeric CD8 consisting of both α and β chains. For tracking CD4 T cells (CD4 consists of a single chain), two anti-CD4 mAb clones that do not compete for the same binding sites are optimal. For example, this can be achieved by i.v. injection of anti-CD4 mAb clone RM4-4 followed by ex vivo staining with clone RM4-5 (Fig. 2b) . Alternatively, a mAb specific for CD45 (Fig. 2c) , a pan-leukocyte marker, is useful if you are contemporaneously examining multiple leukocyte lineages in one mouse or if the use of anti-CD8β must be avoided; for instance, CD8β staining can block staining with peptide:major histocompatibility complex (MHC) I tetramers 42 . In this case, we have used the same mAb clone for both intravascular and ex vivo staining (anti-CD45.2 mAb clone 104). This strategy could be pursued for other markers, particularly when only one mAb clone is available for a marker of interest ( Fig. 2d shows dual staining with the anti-CD8α clone 53-6.7 as an example). However, this approach may diminish the intensity of the ex vivo staining. Although other mAb combinations may suit investigators' unique goals, it is important to avoid i.v. injection of complement-fixing mAb that may rapidly eliminate labeled cells. Although several antibodies with different fluorescent tags can be mixed and injected intravenously, this option will use up fluorescent channels, and it may reduce the number of markers an investigator can examine ex vivo. When possible, investigators are advised to use a single intravascular Ab specific for all cell types of interest, as this also may reduce the cost of reagents. As shown previously 43 , when examining the spleen, intravascular staining discriminates between cells occupying red pulp (i.v. stain positive) and white pulp (i.v. stain negative, Fig. 2e-g ). When injecting anti-CD45 mAb, the marginal zone is stained particularly brightly. However, among T cells, CD45 staining in splenic red pulp is less intense than the vascular compartments of other tissues (lung, for example) or peripheral blood (Fig. 2h) .
15|

Intravascular staining is confined to vascular cells
In the lung, confocal and epifluorescence microscopy shows that lymphocytes stained with intravascular Ab are present within the vasculature (Fig. 3) . Cells stained with i.v. mAb were truly confined to CD31 + vessels, whereas cells protected from the i.v. mAb were present outside of capillaries, including the pulmonary epithelium, iBALT, airway lamina propria, surrounding large blood vessels, as well as pericapillary and lung airway compartments (Fig. 3b-e , supplementary Videos 1 and 2 and data not shown). These data demonstrate, as expected, that CD8 T cells stained with intravascular Ab within the lung are confined to vasculature, and CD8 T cells protected from intravascular staining are outside of vasculature.
Although perfusion fails to completely remove 'contaminating' vascular lymphocytes from many tissues (Fig. 1) , it should also be noted that vascular lymphocyte populations are also often of interest [15] [16] [17] [18] . For example, histological examination of the lymph nodes of mice that were not perfused confirms that i.v. mAb-labeled CD8 T cells are largely contained within HEVs (Fig. 3f,g ), and they probably represent marginated cells preparing for lymph node entry. Thus, intravascular staining may be a useful approach to identify this population for further characterization. Permissiveness to intravascular Ab labeling in additional tissues will be shown in Figure 4 . In summary, perfusion is unnecessary if intravascular staining is incorporated, and neglecting to perfuse has advantages.
Intravascular staining reveals unique lymphocyte subsets in tissues
Intravascular staining can also be used in the context of polyclonal endogenous CD4 and CD8 T-cell responses. For example, 12 d after i.t. LCMV infection, H-2D b /gp33 MHC I tetramers and I-A b /gp66 MHC II tetramers were used to identify LCMV-specific CD8 and CD4 T cell responses, respectively (Fig. 4a) .
In this case, vascular T cells were identified via injection of anti-CD45.2 mAb, but mice were not perfused. All examined tissues contained LCMV-specific CD8 and CD4 T cells that were labeled by i.v.-injected mAb (Fig. 4b,c) , and immunohistochemical analysis confirmed that T cells exposed to i.v. mAb were associated with CD31 + blood vessels in NLT (supplementary Fig. 1 ). Consistent with reports that CD69 expression on T cells is a marker of tissue residence 9, 10, 38, 47, 48 , CD69 + T cells were only found in the compartment of NLT protected from the i.v. mAb, with the exception of cells isolated from the liver. These results are in keeping with published reports suggesting that liver may contain a fraction of sinusoidal resident CD8 T cells 9, 14 . CD69 expression profiles in tissues were similar 12 and 30 d after infection (data not shown).
The proportion of i.v. protected LCMV-specific CD4 T cells in tissues is typically greater than that observed for CD8 T cells, particularly in the lung ( Fig. 4d and supplementary Fig. 2 ).
In the context of M. tuberculosis infection, intravascular staining also discriminates between the function and phenotype of local T cells truly within the lung as compared with those in vasculature (Fig. 4e and data not shown) . M. tuberculosis causes a chronic lung infection that is contained, but not eliminated, by local immune responses. Twelve-week-old C57BL/6 mice were infected with 100-150 c.f.u. of aerosolized M. tuberculosis (strain H37Rv); anti-CD45.2 mAb was injected i.v. 24 d later, and leukocytes from the lungs, bronchioalveolar lavage (BAL) of the lung airways and blood were evaluated. Intravascular staining confirms that I-A b ESAT-6 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and K b TB10.3/4 4-11 tetramer + T cells (which identify M. tuberculosisspecific CD4 and CD8 T cells, respectively) have varied PD-1 expression, a receptor that inhibits T cell function and is regulated by antigen stimulation (Fig. 4f,g ). Among both antigen-specific CD4 and CD8 T cells, PD-1 is more highly expressed on cells protected from intravascular staining compared with i.v. labeled cells present in vasculature (Fig. 4h) . These data reinforce that intravascular staining has the potential to refine our understanding of local immune control over M. tuberculosis. 
Intravascular staining indicates anatomic localization of b cells
Intravascular staining can also be applied for refining the anatomic compartmentalization of different B-cell subsets 43 . A 13-parameter flow cytometry panel was used to phenotypically identify Ab-secreting (intracellular Ig high), B1 (B220 low , CD43 + ), germinal center (B220 + , CD43 low , CD38 low , GL7 + ), switched memory (CD19 + , B220 + , CD38 + , IgM/IgD − ) or naive and unswitched memory (CD19 + , B220 + , CD38 + , IgM/IgD + ) B cells after LCMV infection (Fig. 5) .
In the spleen, Ab-secreting and germinal center B cells were protected from i.v. anti-CD45.2 mAb (12 d after i.t. challenge with LCMV, Fig. 5b,d) , consistent with preferential localization to white pulp follicles [44] [45] [46] . Although B1, naive, unswitched memory and switched memory B cells were also predominantly protected from i.v. mAb staining, ~30% of each subset was exposed to i.v. mAb (Fig. 5c,e,f) . These data demonstrate how intravascular staining approaches can be applied to examine B cells. 
Intravascular staining during Mtb infection reveals distinct myeloid subsets
Intravascular staining can also delineate differences between vascular and tissue cells of the myeloid lineage. Fourteen-parameter flow cytometry can be used to measure markers characteristic of neutrophils (Ly6G, clone IA8) and mononuclear phagocytes (intracellular CD68 + ; these include monocytes, macrophages and dendritic cells, DCs) (Fig. 6) . Neutrophils can be isolated from the lungs of naive mice, regardless of perfusion (Fig. 6b) , even though neutrophils are not prototypically present in healthy tissues. However, the use of intravascular staining demonstrates that all of the isolated neutrophils from the naive lung were labeled with the i.v. mAb, confirming that they are not in the pulmonary tissue of uninfected mice and that perfusion failed to remove them from vasculature (Fig. 6c) . Both i.v. mAb-labeled and unlabeled CD68 + mononuclear phagocytes were recovered, consistent with the fact that certain myeloid cells are present both in blood and in tissue parenchyma and airways at steady state 49 (Fig. 6d) .
To illustrate that bona fide pulmonary neutrophils are protected from intravascular staining, we evaluated the intravascular staining technique in M. tuberculosis infection, a situation in which neutrophils localize to lung tissue. Unlike in uninfected mice, approximately half of the neutrophils recovered from the lung are protected from i.v. mAbs (PBL and BAL served as positive and negative staining controls, respectively, Fig. 6e,f) . Similarly, and consistent with enhanced recruitment of myeloid cells to the lung between 3 and 4 weeks after M. tuberculosis infection 35, 50 , the proportion of unlabeled CD68 + mononuclear phagocytes also increases after M. tuberculosis infection compared with naive mice (Fig. 6g) . CD6 8 + cells can further discriminate various pulmonary myeloid subsets, such as inflammatory monocytes/macrophages (Ly6C + , CD11b + , CD11c − ), conventional DCs (cDCs; CD11b + /CD11b − and CD11c + ), tissue-resident CD103 + cDCs (CD103 + , CD11c + , CD11b − ) and inflammatory monocyte-derived DCs (moDCs; Ly6C + , CD11c + CD11b + ) 11, 51 . As expected, CD103 + cDCs isolated from the lung were indeed protected from intravascular mAb staining (Fig. 6h,j) . Ly6C + , CD11c -monocytes/macrophages were largely contained in the i.v. labeled fraction (Fig. 6i,j) consistent with the idea that the majority of this subset represents true monocytes present in pulmonary blood vasculature, whereas only a minority were tissue-localized bona fide macrophages. It should be noted that previously the Ly6C + , CD11c − population was found to be seemingly homogeneous with uniform expression of over 50 phenotypic markers of interest 35 (data not shown), highlighting the crucial importance of the intravascular staining technique in distinguishing pulmonary Ly6C + inflammatory monocytes from macrophages. Moreover, inflammatory moDCs (CD11b + , CD11c + , Ly6C + ) represent the major myeloid cell type truly present in the lungs of M. tuberculosis-infected mice, as they were completely protected from i.v. mAb labeling (Fig. 6j) . These inflammatory moDCs have recently been shown to be highly multifunctional, producing interleukin (IL)-1α, IL-1β, tumor necrosis factor (TNF)α, inducible nitric oxide synthase (iNOS) and IL-10, and they are phenotypically characterized by high toll-like receptor 2 (TLR2), CD13, Ly6C and CD64 expression 35 . Thus, the use of the intravascular staining technique uniquely enabled the enrichment and recovery of inflammatory moDCs as myeloid effector cells in lung tissue in response to M. tuberculosis infection, another observation otherwise obscured by the presence of large numbers of myeloid cells in the lung blood vasculature.
Intravascular staining reveals distinct leukocyte subsets in tumor-bearing tissue
Intravascular staining can also distinguish cells in a noninfectious disease model. As an illustration, we phenotypically analyzed T cells and myeloid cells in a solid tumor model of renal cancer 36, 37 . Mouse Renca cells were injected into the left kidneys of 8-week-old BALB/c mice. Tumor nodules were detectable histologically in the left kidneys 14 d later (Fig. 7a) . When a polyclonal Ab against collagen was injected i.v., it labeled glomerular basement membrane, but it did not infiltrate the tumor (data not shown), illustrating that i.v.-injected Ab staining was limited to vascular-localized epitopes. In separate mice, anti-CD45.2 mAb was injected i.v., and then cells isolated from blood, tumor-bearing kidneys and non-tumorbearing contralateral kidneys were examined. As expected, intravascular staining reveals striking phenotypic differences among T cells within tumor-bearing kidney compared with those in control kidney tissue and also blood (Fig. 7b-e) . For instance, ~30% of CD4 T cells protected from i.v. mAb staining isolated from tumor-bearing tissue coexpressed CD69 and CD103, a phenotype suggestive of regulatory T cells that may interfere with tumor immune responses. The inhibitory molecule PD-1, which is expressed upon cognate Ag stimulation, was expressed by most CD45.2 unlabeled T cells in tumor-bearing kidneys. This observation provides further evidence that intravascular staining may be used to identify tumor-infiltrating lymphocytes.
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that can both suppress antitumor immune responses and promote cancer 52 . The presence and subsequent suppressive capacity of MDSCs have been reported in both human renal cell patients and Renca murine models 53, 54 . Two main subsets of MDSCs exist on the basis of their Ly6G expression 52 , which have been shown to be phenotypically and functionally distinct 55, 56 . Therefore, understanding where they reside within the tumor-bearing kidney can shed light on their functional capabilities and suppressive mechanisms. Anti-CD45.2 i.v. mAb staining on both Ly6G + and Ly6G -MDSC subsets confirms that these subsets are differentially distributed between vasculature and tumor-bearing kidney tissue in a Renca solid tumor model (Fig. 7f) . Ly6G + MDSCs were predominantly found in Renca tumors, whereas Ly6G − MDSCs were isolated from both tumor tissue and vasculature (Fig. 7g,h) . Together, these data demonstrate that intravascular staining is also a useful tool to refine our understanding of antitumor immune responses.
concluding remarks
Intravascular staining has previously been used to distinguish between single populations of leukocytes in the vascular circulation and those in the tissue of the lung 12, 13, 32, 48, 57, 58 or the red and white pulp of the spleen 43 . Moreover, perfusion was shown to inefficiently remove CD8 T cells from the lung vasculature 13 . The typical results shown here demonstrate the true scope of this issue by showing that cells of both the adaptive and innate immune system accumulate in the vasculature of many tissues and in the disease models examined. Perfusion not only fails to remove many vascular-bound leukocytes but it may also disrupt novel tissue populations such as alveolar lymphoid aggregates. No specific problems with intravascular staining were encountered in any of the models presented.
Findings from numerous studies 13, 32, 57 in addition to the sample data presented here invite reassessment of the widely used practice of perfusion. Moreover, they provide a compelling rationale for the incorporation of intravascular staining when possible, without perfusion, when studying any tissue leukocyte population. In fact, this approach may be absolutely necessary to capture an accurate representation of the local participants in immune-mediated protection and disease. 
